cerdulatinib

August 9, 2019September 9, 2019

Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show

News

Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according ... Read more

October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more

June 7, 2018

Cerdulatinib Shows Promising Phase 2a Trial Results in Blood Cancer Patients, Including NHL

News

Portola Pharmaceuticals‘ investigative therapy cerdulatinib is effective and well-tolerated in patients with several types of blood cancer, including non-Hodgkin’s lymphoma, who failed multiple prior therapies, according to interim results of ... Read more

June 4, 2015

Portola Pharmaceuticals Announces Encouraging Results For Cerdulatinib in Hematologic Cancer Patients

News

Portola Pharmaceuticals, Inc., a biopharmaceutical company focused on thrombosis and other hematologic diseases, recently announced positive safety and efficacy data on its product cerdulatinib in patients with hematologic cancers who ... Read more